Cost accounting supports clinical evaluations

Healthcare Financial Management, April, 1994 by Caryl E. Carpenter, Linda C. Weitzel, Nelda E. Johnson, David B. Nash

a. Razaee, Z., "Examining the effects of PPS on cost accounting systems," Health-care Financial Management, March 1993, pp. 58-62.

b. Nemes, J., "Tight margins lead hospitals to cost accounting systems," Modern Health-care, December 17, 1990, pp. 22-27.

c. Krueger, D.J., and T.A. Davidson, "Alternative Approaches to Cost Accounting," Topics in Health Care Financing, Summer 1987, pp. 1-9.

d. Milne, R.J., and R.C. Heel, "Ondansertron: Therapeutic use as an antiemetic," Drugs April 1991, pp. 574-595.

e. "F-D-C Reports: The Pink Sheet," September 23, 1991.

f. Meyer, B.R., "Biotechnology and therapeutics: Expensive treatments and limited resources. A view from the hospital," Clinical Pharmacology & Therapeutics, April 1992, pp. 359-365.

Caryl E. Carpenter, PhD, is assistant professor, Widener University, Chester, Pennsylvania, and a member of HFMA's Metropolitan Philadelphia Chapter.

Linda C. Weitzel, MBA, is director of financial planning, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, and a member of HFMA's Metropolitan Philadelphia Chapter.

Nelda E. Johnson, Pharm.D, is project director, health policy & clinical outcomes, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.

David B. Nash, MD, MBA, is director, health policy and clinical outcomes, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.